Pre-made Romosozumab benchmark antibody ( Whole mAb, anti-SOST therapeutic antibody, Anti-CDD/DAND6/VBCH Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-493
                                      Pre-Made Romosozumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture,  assay development,  animal model development,  PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price | 
|---|---|---|---|---|
| GMP-Bios-ab-493-1mg | 1mg | 3090 | Inquiry | Inquiry | 
Size: 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Romosozumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody | 
| INN Name | Romosozumab | 
| Target | SOST | 
| Format | Whole mAb | 
| Derivation | Humanized | 
| Species Reactivity | Human | 
| CH1 Isotype | IgG2 | 
| VD LC | Kappa | 
| Highest_Clin_Trial (Jan '20) | Approved | 
| Est. Status | NFD | 
| 100% SI Structure | None | 
| 99% SI Structure | None | 
| 95-98% SI Structure | None | 
| Year Proposed | 2011 | 
| Year Recommended | 2012 | 
| Companies | ChiroscienceGroup plc;Amgen;UCB | 
| Conditions Approved | Male osteoporosis;Postmenopausal osteoporosis | 
| Conditions Active | na | 
| Conditions Discontinued | Fracture | 
| Development Tech | na | 
        <
                
                
            
        
        

